By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Santen Pharmaceutical Co., Ltd. 

3-9-19 Shimo-Shinjo Higashi Yodogawa-ku

Osaka    533  Japan
Phone: 81-0-6-3217000 Fax: 81-0-6-3285082



Company News
R-Tech Ueno: Announcement On Acquisition Of The Right To Develop And Commercialize DE-105 From Santen Pharmaceutical 4/27/2015 10:54:10 AM
Santen Pharmaceutical Announces Approval Of Ikervis For EU Marketing Authorization 3/25/2015 8:00:04 AM
Santen Pharmaceutical Release: Increase Of Capital For A Consolidated Subsidiary In Europe 9/25/2014 7:55:10 AM
Santen Pharmaceutical Facilitates Compliance, Promotes Safety, And Supports Growth With Oracle (ORCL) Argus Cloud Service 7/9/2014 2:10:24 PM
Merck & Co., Inc. (MRK) Signs Sale Agreement With Santen Pharmaceutical For Merck's Ophthalmology Products In Japan And Key Markets In Europe And Asia Pacific 5/13/2014 6:40:49 AM
Santen Pharmaceutical And TRACON Pharmaceuticals, Inc. Announce Agreement For The Development And Commercialization Of TRC105 In Ophthalmology 3/4/2014 11:38:33 AM
Santen Pharmaceutical Announces the Appointment of Naveed Shams, M.D., Ph.D. as the President and CEO 3/12/2013 9:39:52 AM
Santen Pharmaceutical and Clearside Biomedical Enter Into Financing and Research Collaboration Agreements for Posterior Ocular Disease 1/31/2013 10:18:08 AM
Eisai Company, Ltd. (ESALY.PK) and Santen Pharmaceutical Enter Into Option Agreement for New Ophthalmic Drugs 9/27/2012 4:14:34 PM
Santen Pharmaceutical Nabs Japanese Co-Promotion Rights to Bayer HealthCare (BAY) and Regeneron Pharmaceuticals, Inc. (REGN)'s Eylea 5/8/2012 6:55:17 AM